Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebo-controlled intervention trial.

Svensson M, Schmidt EB, Jørgensen KA, Christensen JH; OPACH Study Group.

Clin J Am Soc Nephrol. 2006 Jul;1(4):780-6. Epub 2006 Jun 14.

2.

The effect of n-3 fatty acids on lipids and lipoproteins in patients treated with chronic haemodialysis: a randomized placebo-controlled intervention study.

Svensson M, Schmidt EB, Jørgensen KA, Christensen JH.

Nephrol Dial Transplant. 2008 Sep;23(9):2918-24. doi: 10.1093/ndt/gfn180. Epub 2008 Apr 24.

PMID:
18436564
3.

The effect of n-3 fatty acids on heart rate variability in patients treated with chronic hemodialysis.

Svensson M, Schmidt EB, Jørgensen KA, Christensen JH.

J Ren Nutr. 2007 Jul;17(4):243-9.

PMID:
17586422
4.

The effect of n-3 fatty acids on C-reactive protein levels in patients with chronic renal failure.

Madsen T, Schmidt EB, Christensen JH.

J Ren Nutr. 2007 Jul;17(4):258-63.

PMID:
17586424
5.

The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial.

Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W.

Circulation. 2003 Feb 25;107(7):992-5.

6.

n-3 fatty acids and the risk of sudden cardiac death. Emphasis on heart rate variability.

Christensen JH.

Dan Med Bull. 2003 Nov;50(4):347-67. Review.

PMID:
14694851
7.

The content of docosahexaenoic acid in serum phospholipid is inversely correlated with plasma homocysteine levels in patients with end-stage renal disease.

Rasmussen LE, Svensson M, Jørgensen KA, Schmidt EB, Christensen JH.

Nutr Res. 2010 Aug;30(8):535-40. doi: 10.1016/j.nutres.2010.07.004.

PMID:
20851307
9.

Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI-HF trial.

Marchioli R, Levantesi G, Silletta MG, Barlera S, Bernardinangeli M, Carbonieri E, Cosmi F, Franzosi MG, Latini R, Lucci D, Maggioni AP, Moretti L, Nicolosi GL, Porcu M, Rossi MG, Tognoni G, Tavazzi L; GISSI-HF Investigators.

Expert Rev Cardiovasc Ther. 2009 Jul;7(7):735-48. doi: 10.1586/erc.09.70.

PMID:
19589110
10.

Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events.

Vianna AC, Mocelin AJ, Matsuo T, Morais-Filho D, Largura A, Delfino VA, Soares AE, Matni AM.

Hemodial Int. 2007 Apr;11(2):210-6.

PMID:
17403173
13.

Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study.

Limbs International Medicinal Buflomedil (LIMB) Study Group, Leizorovicz A, Becker F.

Circulation. 2008 Feb 12;117(6):816-22. doi: 10.1161/CIRCULATIONAHA.107.706374. Epub 2008 Jan 22.

14.

Highly purified omega-3 polyunsaturated fatty acids are effective as adjunct therapy for secondary prevention of myocardial infarction.

Verboom CN; Critical Analysis of GISSI-Prevenzione Trial.

Herz. 2006 Dec;31 Suppl 3:49-59.

PMID:
17575805
15.

Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS).

Li JJ, Lu ZL, Kou WR, Chen Z, Wu YF, Yu XH, Zhao YC; Chinese Coronary Secondary Prevention Study Group.

J Clin Pharmacol. 2009 Aug;49(8):947-56. doi: 10.1177/0091270009337509.

PMID:
19602720
16.

Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial.

Zoungas S, McGrath BP, Branley P, Kerr PG, Muske C, Wolfe R, Atkins RC, Nicholls K, Fraenkel M, Hutchison BG, Walker R, McNeil JJ.

J Am Coll Cardiol. 2006 Mar 21;47(6):1108-16. Epub 2006 Feb 23.

17.

n-3 fatty acids and revascularization procedures.

Arnesen H.

Lipids. 2001;36 Suppl:S103-6. Review.

PMID:
11837981
18.

Effect of n-3 fatty acids on carotid atherosclerosis and haemostasis in patients with combined hyperlipoproteinemia: a double-blind pilot study in primary prevention.

Baldassarre D, Amato M, Eligini S, Barbieri SS, Mussoni L, Frigerio B, Kozàkovà M, Tremoli E, Sirtori CR, Colli S.

Ann Med. 2006;38(5):367-75.

PMID:
16938806
19.
20.

Can n-3 PUFA reduce cardiac arrhythmias? Results of a clinical trial.

Singer P, Wirth M.

Prostaglandins Leukot Essent Fatty Acids. 2004 Sep;71(3):153-9.

PMID:
15253884

Supplemental Content

Support Center